Table 1.

Comparion of recent CV outcomes trials completed with GLP-1RAs and SGLT2 inhibitors

	GLP-1RA				SGLT2 inhibitor
	Once-daily		Once-weekly
	ELIXA (lixisenatide)	LEADER (liraglutide)	SUSTAIN-6 (semaglutide)	EXSCEL (exenatide)	EMPA-REG OUTCOME (empagliflozin)	CANVASa (canagliflozin)
Patient number	6058	9340	3297	14,752	7020	10,142
Median follow-up duration (years)	2.1	3.8	2.1	3.2	3.1	2.4
Key eligibility	T2D with recent ACS	T2D with high CV risk	T2D with high CV risk	T2D with high CV risk	T2D with previous CV disease	T2D with high CV risk
Prior CV disease (%)	100	81	60	73	99	66
Mean baseline HbA1c (%)	7.7	8.7	8.7	8.0	8.1	8.2
Metformin use (%)	66	76	73	77	74	77
Statin use (%)	93	72	73	74	77	75
RAAS inhibitor use (%)	85	83	84	80	81	80
Outcomes (HR [95% CI])
MACEb	1.02 [0.89–1.17]	0.87 [0.78–0.97]	0.74 [0.58–0.95]	0.91 [0.83–1.00]	0.86 [0.74–0.99]	0.86 [0.75 – 0.97]
CV death	0.98 [0.78–1.22]	0.78 [0.66–0.93]	0.98 [0.65–1.48]	0.88 [0.76–1.02]	0.62 [0.49 – 0.77]	0.87 [0.72–1.06]
Myocardial infarction	1.03 [0.87–1.22]	0.86 [0.73–1.00]	0.74 [0.51–1.08]	0.97 [0.85–1.10]	0.87 [0.70–1.09]	0.85 [0.69–1.05]
Stroke	1.12 [0.79–1.58]	0.86 [0.71–1.06]	0.61 [0.38–0.99]	0.85 [0.70–1.03]	1.18 [0.89–1.56]	0.90 [0.71–1.15]
All-cause death	0.94 [0.78–1.13]	0.85 [0.74–0.97]	1.05 [0.74–1.50]	0.86 [0.77–0.97]	0.68 [0.57 – 0.82]	0.87 [0.74–1.01]
Hospitalization for heart failure	0.96 [075–1.23]	0.87 [0.73–1.05]	1.11 [0.77–1.61]	0.94 [0.78–1.13]	0.65 [0.50 – 0.85]	0.67 [0.52 – 0.87]
Composite renal outcomes	–	0.78 [0.67–0.92]	0.64 [0.46–0.88]	–	0.61 [0.53 – 0.70]	0.60 [0.47–0.77]

Italic values indicate significance of p value (p < 0.05)

ACS acute coronary syndrome, CI confidence interval, CV cardiovascular, GLP-1RA glucagon-like peptide-1 receptor agonist, MACE major adverse cardiovascular events, HR hazard ratio, RAAS renin–angiotensin–aldosterone system, SGLT2 sodium-glucose cotransporter 2, T2D type 2 diabetes

^aPooled data from CANVAS and CANVAS-R

^b4-point MACE in the ELIXA trial and 3-point MACE in the other trials